Opus Genetics, Inc.

NASDAQ:IRD

Biotechnology

Healthcare
$3.92 -0.12%

-$0.01 today

Market cap
$326.13M
Beta
0.55
P/E (TTM)
-33.0
EPS (TTM)
-$0.12
52W Low $0.90High $5.81

Volume 0.75M

Average 0.81M

IRD Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Opus Genetics, Inc.NASDAQ: IRD

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 868.91M shares rose 2464.3% year over year, ahead of the +1283.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 39.6% from the prior quarter. Over 3 fiscal years it compounded at +211.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2464.3% holds above the trailing-twelve-month pace of +1283.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
868.91M+39.6% QoQ
Last fiscal yearDec 2025
622.22M+2229.1% YoY
LTMMar 2026
406.29M+1283.9% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2464.3%——
1 year+2229.1%——
3-year CAGR+211.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
622.22M USD
Year-over-year change
+2229.1%
4-year CAGR
+154.4%

Weighted Avg Shares (Diluted) vs competitors

How IRD compares with its peers on the latest reported figures

  • IRD's LTM Mar 2026 weighted avg shares (diluted) of 406.29M shares is the highest of the 10 companies compared; the peer median is 56.96M shares.
  • Its year-over-year change of +1283.9% is the highest of 10, against a peer median of +10.4%.
  • Over three fiscal years its annual growth of +211.4% compares with a peer median of +18.0%.
IRD Competitors Peer median
Weighted Avg Shares (Diluted) for IRD and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+211.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026312.72M +1040.7%+186.8%
ALECAlector, Inc.LTM Mar 2026104.14M +6.5%+7.7%
CGTXCognition Therapeutics, Inc.LTM Mar 202679.93M +69.4%+35.9%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 202661.23M +1.8%+14.3%
SEERSeer, Inc.LTM Mar 202656.96M -7.5%-2.7%
HURATuHURA Biosciences, Inc.LTM Mar 202650.79M +127.0%+911.7%
AGENAgenus Inc.LTM Mar 202633.65M +50.2%+28.3%
MCRBSeres Therapeutics, Inc.LTM Mar 20268.99M +10.4%+18.0%
TILInstil Bio, Inc.LTM Mar 20266.73M +3.3%+1.0%
Peer median (excluding IRD) 56.96M+10.4%+18.0%

Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue589K39.85M19.05M10.99M14.2M
Cost of Revenue00000
Gross Profit589K39.85M19.05M10.99M14.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development15.17M14.36M17.65M26.85M30.81M
Selling, General & Admin8.12M7.27M11.96M18.22M21.98M
Operating Expenses23.29M21.62M29.61M73.07M52.8M
Depreciation & Amortization4K4K6K10K53K
EBITDA(56.69M)18.22M(9.97M)(57.52M)(48.07M)
EBITDA Margin-9624.3%45.7%-52.3%-523.3%-338.6%
Operating Income(22.71M)18.23M(10.56M)(62.07M)(38.6M)
Operating Margin-3854.8%45.7%-55.5%-564.7%-271.9%
Interest Income00000
Interest Expense2K9K1.33M01.47M
Other Income / Expenses(33.99M)(23K)589K4.54M(10.99M)
Income Before Tax(56.69M)18.2M(9.97M)(57.53M)(49.59M)
Pre-Tax Margin-9625.3%45.7%-52.4%-523.4%-349.3%
Income Tax Expense0315K12K00
Net Income(56.69M)17.89M(9.99M)(57.53M)(49.59M)
Net Margin-9625.3%44.9%-52.4%-523.4%-349.3%
EPS (Basic)(3.82)0.90(0.46)(2.15)(0.80)
EPS (Diluted)(3.82)0.87(0.46)(2.15)(0.80)
Weighted Avg Shares14.85M19.93M21.59M26.72M622.22M
Weighted Avg Shares (Diluted)14.85M20.6M21.59M26.72M622.22M

Opus Genetics, Inc.

NASDAQ:IRD

Intrinsic Alpha fair value

Locked

Current Price

$3.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.